Graft versus host disease prophylaxis in patients receiving stem cell transplantation due to: chronic myeloid leukemia (CML) in 1st or 2nd chronic phase, acute myeloid leukemia (AML) in complete remission, acute lymphoblastic leukemia (ALL) in complete remission, myelodysplastic syndrome, chronic lymphocytic leukemia, lymphoma, non-malignant disorders, severe aplastic anemia, hemoglobinopathies and metabolic disorders MedDRA version: 9.1 Level: LLT Classification code 10018799 Term: GVHD
Conditions
Interventions
Trade Name: Rapamune
Product Name: Rapamune
Pharmaceutical Form: Tablet
INN or Proposed INN: SIROLIMUS
CAS Number: 53123889
Other descriptive name: Rapamycin
Concentration unit: µg/ml microgram(s)/mil
Sponsors
Karolinska Institutet
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who receives bone marrow or peripheral blood stem cells from an HLA-identical sibling donor or an unrelated genomically matched HLA-A, -B and -DRb1 identical donor. No more than one alleles mismatch is allowed. The study includes children and adults undergoing full myeloablative or non-myeloablative conditioning, according to established protocols. Chronic myeloid leukemia (CML) in 1st or 2nd chronic phase, acute myeloid leukemia (AML) in complete remission, acute lymphoblastic leukemia (ALL) in complete remission, myelodysplastic syndrome, chronic lymphocytic leukemia, lymphoma, non-malignant disorders, severe aplastic anemia, hemoglobinopathies and metabolic disorders. More or less all diagnoses where there is an indication for hematopoietic stem cell transplantation with a related or unrelated HLA-identical donor may be included in the study. The inclusion of various cohorts of patients is at the discretion of each participating center – i.e., some centers may only want to include unrelated donors, other may want to include related and unrelated donors, and other centers may be more specific with regard to the various diagnoses Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Recipients of major HLA-mismatched grafts. Patients who are addicted to drugs or alcohol. Patients who receive other stem cell source than bone marrow or peripheral stem cells, for instance cord blood transplants. Patients with relapse or blast crisis of their malignant disease. Prior allogeneic transplant using any hematopoietic stem cell source Seropositive for the human immunodeficiency virus (HIV) Uncontrolled bacterial, viral, or fungal infection (progression of clinical symptoms) Pregnant (positive serum human chorionic gonadotropin [ß-HCG] test) or breastfeeding within 4 weeks of study entry Kidney function: serum creatinine outside the normal range for age, or measured creatinine clearance less than 40 mL/min/1.72m² within 4 weeks of study entry and proteinuria >0.3 g/day Liver function: most recent direct bilirubin, ALT, or AST greater than two times the upper limit of normal within 4 weeks of study entry Lung disease: in adults, FVC or FEV1 less than 60% of predicted value (corrected for hemoglobin); in children, overt hypoxemia, as measured by an oxygen saturation of less than 92% within 4 weeks of study entry Cardiac ejection fraction of less than 45% in adults and children, or less than 26% shortening fraction in children within 4 weeks of study entry Cholesterol level greater than 300 mg/dL or triglyceride level greater than 300 mg/dL while being treated, or not on appropriate lipid-lowering therapy within 4 weeks of study entry Karnofsky score <70% Prior history of allergy to sirolimus Requires voriconazole at time of study entry Currently receiving another investigational drug unless cleared by the principal investigator and sponsor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To evaluate if the immunosuppressive prophylaxis with tacrolimus and sirolimus is better than the established therapy using cyclosporine and methotrexate in preventing graft versus host disease;Secondary Objective: None;Primary end point(s): The primary endpoint is grade II-IV acute GVHD in the two groups. GVHD is diagnosed clinically and graded from 0 to IV, according to previously published criteria. The diagnosis is clinical and biopsies from skin, liver and gut is used according to the routines at each participating center | — |
Countries
Finland, Sweden
Outcome results
None listed